OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

Starting soon · Phase 1

Conditions studied: Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma

In brief

This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.

Key facts

Study ID

NCT07739017

Run by

Olivia Newton-John Cancer Research Institute

People needed

54

Starts

2026-12-01

Expected to finish

2028-09-01

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female aged ≥ 18 years at the time of signing informed consent
• Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System
• KPS score ≥ 70
• Adequate organ function
• Contraception during study participation, as applicable
• Able to swallow tablets

You may not qualify if…

• Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA)
• Placement of Gliadel wafers or similar local therapy at time of surgery
• Receive bevacizumab
• Evidence of intracranial or intra-tumoral hemorrhage
• Significant concomitant disorder or serious intercurrent illness
• History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years
• Treatment for HIV, hepatitis B, or hepatitis C
• Any gastrointestinal disorder that could result in reduced absorption of CT-179
• Any psychiatric illness or social situation that would limit compliance with study requirements
• Dose of dexamethasone higher than 4 mg/day within 1 week of the first dose of study medication

Where it is running

• Royal Brisbane and Women's Hospital — Herston, Queensland, Australia
• Austin Health — Heidelberg, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.